Rapid identification of Mycobacterium tuberculosis infection  by Richeldi, L.
REVIEW
Rapid identiﬁcation of Mycobacterium tuberculosis infection
L. Richeldi
Clinic of Respiratory Diseases, University of Modena and Reggio Emilia, Modena, Italy
ABSTRACT
The conventional intradermal tuberculin skin test (Mantoux test) is poorly speciﬁc and has unknown
sensitivity for latent Mycobacterium tuberculosis infection. Two new tests offer the promise of improved
tuberculosis diagnosis: the QuantiFERON
TM
-TB Gold test, based on a whole blood ELISA, and the T-
SPOT
TM
.TB test, based on the ex-vivo enzyme-linked immunospot (ELISpot) assay. These tests are more
rapid and offer greater speciﬁcity and objectivity than the tuberculin skin tests, and the latter may also
offer greater sensitivity. Both tests have yet to be validated in immunosuppressed patients. Available
evidence suggests that these techniques will be feasible to apply within tuberculosis control
programmes. Ongoing research priorities include head-to-head comparisons, validation in immuno-
suppressed populations, and longitudinal assessment of the predictive value of a positive blood test in
latent infection for progression to active disease.
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INTRODUCTION
The classic diagnostic tool for latent Mycobacteri-
um tuberculosis infection is the tuberculin skin test,
also known as the intradermal Mantoux test.
Developed at the beginning of the twentieth
century, this is the oldest unchanged diagnostic
test still in use in current medical practice.
The tuberculin skin test has two main limita-
tions. First, it is relatively inspeciﬁc. The main
reagent of the tuberculin skin test, the protein
puriﬁed derivative, is a culture ﬁltrate of tubercle
bacilli containing over 200 antigens shared with
the vaccine Bacille Calmette-Gue´rin andmost non-
tuberculous mycobacteria [1]. Thus, individuals
vaccinated against tuberculosis but not infected
with M. tuberculosis can test falsely positive with
the Mantoux test. Second, the tuberculin skin test
has an unknown sensitivity for the diagnosis of
latent M. tuberculosis infection, since a reliable
diagnostic reference standard is lacking.
The high-risk groups that are targeted for
preventive therapy are also those in which the
skin test most often fails to detect M. tuberculosis
infection [2]. Thus, the poor sensitivity of the
Mantoux test has a negative impact on the man-
agement of those groups who would beneﬁt the
most from targeted testing and preventive treat-
ment. This limitation of the skin test also applies to
its use as a diagnostic aid in the evaluation of cases
of suspected active tuberculosis when microbio-
logical conﬁrmation is not possible. Since infection
is a necessary prerequisite for active disease, a
highly sensitive test for M. tuberculosis infection
would help to rule out a diagnosis of active
disease, particularly in immunosuppressed pa-
tients. However, because of its poor sensitivity, a
negative tuberculin skin test in these patients is
almost invariably clinically unhelpful and is not
recommended by current guidelines [3].
NEW TESTS FOR M. TUBERCULOSIS
A new generation of immune-based rapid blood
tests for the diagnosis of latent M. tuberculosis
infection represents a signiﬁcant advance upon
the century-old Mantoux test [4,5]. These tests
possess various characteristics that distinguish
them from their predecessor. Both are based on
the fact that the predominant host response to
mycobacterial infections consists of antigen-spe-
ciﬁc memory T-cells releasing mostly Th1-type
cytokines, mainly interferon-c, in response to
previously encountered mycobacterial antigens.
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The QuantiFERON
TM
-TB Gold test (Cellestis,
Carnegie, Australia) is based on a whole blood
ELISA. This test has been recently approved for
in-vitro diagnostics by the US Food and Drug
Administration (FDA), and its use has been the
subject of a guideline from the US CDC [6]. The
T-SPOT
TM
.TB test (Oxford Immunotec, Abingdon,
UK) is based on the ex-vivo overnight enzyme-
linked immunospot (ELISpot) assay and has been
approved for in-vitro diagnostic use in Europe.
These new tests are the result of mycobacterial
genomic research, since they utilise two proteins
encoded by a unique genomic segment of DNA
termed Region of Difference 1 (RD-1), which is
absent from all strains of the tuberculosis vaccine
and most of the non-tuberculous environmental
mycobacteria [7]. These proteins, ESAT-6 (early
secretory antigenic target protein 6) and CFP10
(culture ﬁltrate protein 10), are major targets for
T-lymphocytes in individuals with latent
M. tuberculosis infection [8]. Thus, these tests
avoid the main cause of the poor speciﬁcity of
the tuberculin skin test.
These new blood tests have an internal positive
control, i.e., a sample well stimulated with a non-
speciﬁc stimulator of interferon-c production by
T-lymphocytes. While a negative tuberculin skin
test result cannot be identiﬁed as a potential false-
negative result, the failure of the positive control
in the new assays provides the important infor-
mation that the test’s result cannot be reliably
interpreted, since it may reﬂect an underlying
immunosuppression.
These blood tests have clear operational
advantages over the traditional skin test, inclu-
ding the avoidance of inter-individual variability
in administration of the test, a more objective
read-out, and a more rapid result (by the next
day). Two further advantages are that there is no
need for a return visit to have the test read,
which will improve the yield of contact investi-
gations, and the fact that repeated blood tests do
not result in the boosting of subsequent tests,
which will allow for repeated screening of
groups at recurrent risk of M. tuberculosis expo-
sure, such as healthcare workers. A signiﬁcant
practical drawback of the blood tests is the fact
that they need to be processed within 6 h from
venipuncture. However, a recent improvement
of the QuantiFERON-TB Gold test—the In-tube
format—promises to increase signiﬁcantly the
test’s usability.
Both blood tests showed a very high speciﬁcity,
and all published studies clearly demonstrate that
both T-SPOT.TB and QuantiFERON-TB Gold are
more speciﬁc than the skin test for the diagnosis
of M. tuberculosis infection [9]. The available
evidence suggests that QuantiFERON-TB Gold
probably has a sensitivity similar to that of the skin
test in immunocompetent individuals with latent
M. tuberculosis infection. T-SPOT.TB appears to be
more sensitive than the Mantoux test for the
detection of M. tuberculosis infection, in particular
in adults and children with HIV co-infection
[10,11]. Like T-SPOT.TB, QuantiFERON-TB Gold
has a higher sensitivity than the skin test in
immunocompetent patients with active tubercu-
losis, but its sensitivity in patients with impaired
cellular immunity has not been evaluated yet.
Case reports have provided interesting initial
evidence of the clinical utility of these tests in
supporting a diagnosis of active tuberculosis in
skin test-negative immunosuppressed patients
[12,13]. Furthermore, recent data suggest that,
although the two tests detect similar immune
responses in the blood, they may provide signiﬁ-
cantly different rates of positive results in various
population groups [14]. Unfortunately, the lack of
a diagnostic reference standard for latent tuber-
culosis infection prevents us from drawing any
ﬁrm conclusions on the sensitivity and speciﬁcity
of the new tests. In any case, the rates of indeter-
minate results (i.e., results lacking a valid response
to the internal positive control) seem to be higher
for QuantiFERON-TB Gold than for T-SPOT.TB, in
particular among immunosuppressed patients
[14].
CLINICAL APPLICATION OF NEW
TESTS
The improved accuracy of these new-generation
tests in the diagnosis of latent infection, coupled
with their advantageous operational characteris-
tics, is likely to improve the effectiveness of
programmes aimed at tuberculosis control. How-
ever, achieving these goals will depend on the
successful application of the new tests under
routine programme conditions. Many reports
indicate that the application of the blood tests
in routine clinical practice diagnostic microbio-
logy laboratories and community-based contact
tracing protocols is feasible. These technologies
also seem to be feasible in relatively rudimentary
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laboratories in developing countries, including
Africa and India [11,15].
Replacement of the tuberculin skin test with the
new blood tests should not change the principles
of targeted testing, which are based on treating
those groups at highest risk of progression to
active tuberculosis [2]. Therefore, the advent of
the new blood tests should not lead to global,
indiscriminate population screening. In practice,
it can be predicted that the higher speciﬁcity of
the new tests will reduce false-positive test results
in vaccinated individuals, thus avoiding the costs
due to unnecessary chemoprophylaxis and its
associated toxicity. Higher sensitivity, on the
other hand, would allow the identiﬁcation of
more infected individuals among those with a
false-negative skin test result. Finally, more true-
positive results in infected individuals will in-
crease the rate of diagnosis and treatment of latent
tuberculosis infection in the most vulnerable
populations before progression to active disease.
The introduction of the new blood tests in
clinical practice would initially increase costs. On
the other hand, their higher diagnostic sensitivity,
coupled with their higher speciﬁcity, could gen-
erate cost savings by reducing the future burden
of cases of active tuberculosis and decreasing the
number of uninfected vaccinated individuals
inappropriately treated with chemoprophylaxis.
CONCLUSIONS
Two new tests have recently offered the promise
of improved diagnosis of M. tuberculosis infection.
Ongoing research priorities include head-to-head
comparative studies of the two tests and the
evaluation of both in the diagnosis of tuberculosis
infection in patients with iatrogenic immunosup-
pression, e.g., resulting from dialysis, organ
transplantation, and anti-tumour necrosis factor-
a treatment. Finally, longitudinal studies of high-
risk cohorts will enable evaluation of the risk of
progression in individuals with positive blood
test results; this will help to deﬁne the positive
predictive value for subsequent development of
active tuberculosis with the new tests.
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